Cargando…

PI3K inhibitors in inflammation, autoimmunity and cancer

The healthy immune system protects against infection and malignant transformation without causing significant damage to host tissues. Immune dysregulation results in diverse pathologies including autoimmune disease, chronic inflammatory disorders, allergies as well as immune deficiencies and cancer....

Descripción completa

Detalles Bibliográficos
Autores principales: Stark, Anne-Katrien, Sriskantharajah, Srividya, Hessel, Edith M, Okkenhaug, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518027/
https://www.ncbi.nlm.nih.gov/pubmed/26093105
http://dx.doi.org/10.1016/j.coph.2015.05.017
_version_ 1782383274426892288
author Stark, Anne-Katrien
Sriskantharajah, Srividya
Hessel, Edith M
Okkenhaug, Klaus
author_facet Stark, Anne-Katrien
Sriskantharajah, Srividya
Hessel, Edith M
Okkenhaug, Klaus
author_sort Stark, Anne-Katrien
collection PubMed
description The healthy immune system protects against infection and malignant transformation without causing significant damage to host tissues. Immune dysregulation results in diverse pathologies including autoimmune disease, chronic inflammatory disorders, allergies as well as immune deficiencies and cancer. Phosphoinositide 3-kinase (PI3K) signalling has been shown to be a key pathway in the regulation of the immune response and continues to be the focus of intense research. In recent years we have gained detailed understanding of PI3K signalling, and saw the development of potent and highly selective small molecule inhibitors, of which several are currently in clinical trials for the treatment of immune-related disorders and cancer. The role of PI3K signalling in the immune response has been the subject of detailed reviews; here we focus on relevant recent progress in pre-clinical and clinical development of PI3K inhibitors.
format Online
Article
Text
id pubmed-4518027
institution National Center for Biotechnology Information
language English
publishDate 2015
record_format MEDLINE/PubMed
spelling pubmed-45180272015-08-01 PI3K inhibitors in inflammation, autoimmunity and cancer Stark, Anne-Katrien Sriskantharajah, Srividya Hessel, Edith M Okkenhaug, Klaus Curr Opin Pharmacol Article The healthy immune system protects against infection and malignant transformation without causing significant damage to host tissues. Immune dysregulation results in diverse pathologies including autoimmune disease, chronic inflammatory disorders, allergies as well as immune deficiencies and cancer. Phosphoinositide 3-kinase (PI3K) signalling has been shown to be a key pathway in the regulation of the immune response and continues to be the focus of intense research. In recent years we have gained detailed understanding of PI3K signalling, and saw the development of potent and highly selective small molecule inhibitors, of which several are currently in clinical trials for the treatment of immune-related disorders and cancer. The role of PI3K signalling in the immune response has been the subject of detailed reviews; here we focus on relevant recent progress in pre-clinical and clinical development of PI3K inhibitors. 2015-06-18 2015-08 /pmc/articles/PMC4518027/ /pubmed/26093105 http://dx.doi.org/10.1016/j.coph.2015.05.017 Text en © 2015 The Authors. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Stark, Anne-Katrien
Sriskantharajah, Srividya
Hessel, Edith M
Okkenhaug, Klaus
PI3K inhibitors in inflammation, autoimmunity and cancer
title PI3K inhibitors in inflammation, autoimmunity and cancer
title_full PI3K inhibitors in inflammation, autoimmunity and cancer
title_fullStr PI3K inhibitors in inflammation, autoimmunity and cancer
title_full_unstemmed PI3K inhibitors in inflammation, autoimmunity and cancer
title_short PI3K inhibitors in inflammation, autoimmunity and cancer
title_sort pi3k inhibitors in inflammation, autoimmunity and cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518027/
https://www.ncbi.nlm.nih.gov/pubmed/26093105
http://dx.doi.org/10.1016/j.coph.2015.05.017
work_keys_str_mv AT starkannekatrien pi3kinhibitorsininflammationautoimmunityandcancer
AT sriskantharajahsrividya pi3kinhibitorsininflammationautoimmunityandcancer
AT hesseledithm pi3kinhibitorsininflammationautoimmunityandcancer
AT okkenhaugklaus pi3kinhibitorsininflammationautoimmunityandcancer